Specifically, high expression of NLRP1 was significantly correlated with poor OS in patients with stages 1–3 cancer (Table 1; p = 0.048, p = 0.004, p = 0.0002), whereas high expression of NLRP3 was only correlated with poor outcome in patients with stage 3 GC (OS, p = 0.0003; FPS, p = 0.021). Here, NLRP3 is linked to gastric cancer.